Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)-Reference-Cited by-同舟云学术

Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)

Published:2024-03-26 Issue:13 Volume:149 Page:993-1003
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Green Jennifer B.¹^ORCID,Everett Brendan M.²^ORCID,Ghosh Alokananda³^ORCID,Younes Naji³^ORCID,Krause-Steinrauf Heidi³^ORCID,Barzilay Joshua⁴⁵^ORCID,Desouza Cyrus⁶^ORCID,Inzucchi Silvio E.⁷^ORCID,Pokharel Yashashwi⁸^ORCID,Schade David⁹^ORCID,Scrymgeour Alexandra¹⁰^ORCID,Tan Meng H.¹¹,Utzschneider Kristina M.¹²^ORCID,Mudaliar Sunder¹³^ORCID,Crandall J.P.,McKee M.D.,Behringer-Massera S.,Brown-Friday J.,Xhori E.,Ballentine-Cargill K.,Duran S.,Estrella H.,Gonzalez de la Torre S.,Lukin J.,Phillips L.S.,Burgess E.,Olson D.,Rhee M.,Wilson P.,Raines T.S.,Boers J.,Costello J.,Maher-Albertelli M.,Mungara R.,Savoye L.,White C.A.,Gullett C.,Holloway L.,Morehead F.,Person S.,Sibymon M.,Tanukonda S.,Adams C.,Ross A.,Balasubramanyam A.,Gaba R.,Gonzalez Hattery E.,Ideozu A.,Jimenez J.,Montes G.,Wright C.,Hollander P.,Roe E.,Jackson A.,Smiley A.,Burt P.,Estrada L.,Chionh K.,Ismail-Beigi F.,Falck-Ytter C.,Sayyed Kassem L.,Sood A.,Tiktin M.,Kulow T.,Newman C.,Stancil K.A.,Cramer B.,Iacoboni J.,Kononets M.V.,Sanders C.,Tucker L.,Werner A.,Maxwell A.,McPhee G.,Patel C.,Colosimo L.,Krol A.,Goland R.,Pring J.,Alfano L.,Kringas P.,Hausheer C.,Tejada J.,Gumpel K.,Kirpitch A.,Schneier H.,AbouAssi H.,Chatterjee R.,Feinglos M.N.,English Jones J.,Khan S.A.,Kimpel J.B.,Zimmer R.P.,Furst M.,Satterwhite B.M.,Thacker C.R.,Evans Kreider K.,Mariash C.N.,Mather K.J.,Ismail H.M.,Lteif A.,Mullen M.,Hamilton T.,Patel N.,Riera G.,Jackson M.,Pirics V.,Aguillar D.,Howard D.,Hurt S.,Bergenstal R.,Carlson A.,Martens T.,Johnson M.,Hill R.,Hyatt J.,Jensen C.,Madden M.,Martin D.,Willis H.,Konerza W.,Yang S.,Kleeberger K.,Passi R.,Fortmann S.,Herson M.,Mularski K.,Glauber H.,Prihoda J.,Ash B.,Carlson C.,Ramey P.A.,Schield E.,Torgrimson-Ojerio B.,Arnold K.,Kauffman B.,Panos E.,Sahnow S.,Bays K.,Berame K.,Cook J.,Ghioni D.,Gluth J.,Schell K.,Criscola J.,Friason C.,Jones S.,Nazarov S.,Rassouli N.,Puttnam R.,Ojoawo B.,Nelson R.,Curtis M.,Hollis B.,Sanders-Jones C.,Stokes K.,El-Haqq Z.,Kolli A.,Tran T.,Wexler D.,Larkin M.E.,Meigs J.,Chambers B.,Dushkin A.,Rocchio G.,Yepes M.,Steiner B.,Dulin H.,Cayford M.,Chu K.,DeManbey A.,Hillard M.,Martin K.,Thangthaeng N.,Gurry L.,Kochis R.,Raymond E.,Ripley V.,Stevens C.,Park J.,Aroda V.,Ghazi A.,Magee M.,Ressing A.,Loveland A.,Hamm M.,Hurtado M.,Kuhn A.,Leger J.,Manandhar L.,Mwicigi F.,Sanchez O.,Young T.,Garg R.,Lagari-Libhaber V.,Florez H.J.,Valencia W.M.,Marks J.,Casula S.,Oropesa-Gonzalez L.,Hue L.,Cuadot A.,Nieto-Martinez R.,Riccio Veliz A.K.,Gutt M.,Kendal Y.J.,Veciana B.,Ahmann A.,Aby-Daniel D.,Joarder F.,Morimoto V.,Sprague C.,Yamashita D.,Cady N.,Rivera-Eschright N.,Kirchhoff P.,Morales Gomez B.,Adducci J.,Goncharova A.,Hox S.H.,Petrovitch H.,Matwichyna M.,Jenkins V.,Broadwater L.,Ishii R.R.,Bermudez N.O.,Hsia D.S.,Cefalu W.T.,Greenway F.L.,Waguespack C.,King E.,Fry G.,Dragg A.,Gildersleeve B.,Arceneaux J.,Haynes N.,Thomassie A.,Pavlionis M.,Bourgeois B.,Hazlett C.,Henry R.,Boeder S.,Pettus J.,Diaz E.,Garcia-Acosta D.,Maggs S.,DeLue C.,Stallings A.,Castro E.,Hernandez S.,Krakoff J.,Curtis J.M.,Killean T.,Khalid M.,Joshevama E.,Diaz E.,Martin D.,Tsingine K.,Karshner T.,Albu J.,Pi-Sunyer F.X.,Frances S.,Maggio C.,Ellis E.,Bastawrose J.,Gong X.,Banerji M.A.,August P.,Lee M.,Lorber D.,Brown N.M.,Josephson D.H.,Thomas L.L.,Tsovian M.,Cherian A.,Jacobson M.H.,Mishko M.M.,Kirkman M.S.,Buse J.B.,Diner J.,Dostou J.,Machineni S.,Young L.,Bergamo K.,Goley A.,Kerr J.,Largay J.F.,Guarda S.,Cuffee J.,Culmer D.,Fraser R.,Almeida H.,Coffer S.,Debnam E.,Kiker L.,Morton S.,Josey K.,Fuller G.,Garvey W.T.,Cherrington A.L.,Dyer D.,Lawson M.C.R.,Griffith O.,Agne A.,McCullars S.,Cohen R.M.,Craig J.,Rogge M.C.,Burton K.,Kersey K.,Wilson C.,Lipp S.,Vonder Meulen M.B.,Adkins C.,Onadeko T.,Rasouli N.,Baker C.,Schroeder E.,Razzaghi M.,Lyon C.,Penaloza R.,Underkofler C.,Lorch R.,Douglass S.,Steiner S.,Sivitz W.I.,Cline E.,Knosp L.K.,McConnell J.,Lowe T.,Herman W.H.,Pop-Busui R.,Martin C.,Waltje A.,Katona A.,Goodhall L.,Eggleston R.,Kuo S.,Bojescu S.,Bule S.,Kessler N.,LaSalle E.,Whitley K.,Seaquist E.R.,Bantle A.,Harindhanavudhi T.,Kumar A.,Redmon B.,Bantle J.,Coe M.,Mech M.,Taddese A.,Lesne L.,Smith S.,Kuechenmeister L.,Shivaswamy V.,Burbach S.,Rodriguez M.G.,Seipel K.,Alfred A.,Morales A.L.,Eggert J.,Lord G.,Taylor W.,Tillson R.,Adolphe A.,Burge M.,Duran-Valdez E.,Martinez J.,Bancroft A.,Kunkel S.,Ali Jamaleddin Ahmad F.,Hernandez McGinnis D.,Pucchetti B.,Scripsick E.,Zamorano A.,DeFronzo R.A.,Cersosimo E.,Abdul-Ghani M.,Triplitt C.,Juarez D.,Mullen M.,Garza R.I.,Verastiqui H.,Wright K.,Puckett C.,Raskin P.,Rhee C.,Abraham S.,Jordan L.F.,Sao S.,Morton L.,Smith O.,Osornio Walker L.,Schnurr-Breen L.,Ayala R.,Kreymer R.B.,Sturgess D.,Kahn S.E.,Alarcon-Casas Wright L.,Boyko E.J.,Tsai E.C.,Trence D.L.,Trikudanathan S.,Fattaleh B.N.,Montgomery B.K.,Atkinson K.M.,Kozedub A.,Concepcion T.,Moak C.,Prikhodko N.,Rhothisen S.,Elasy T.A.,Martin S.,Shackelford L.,Goidel R.,Hinkle N.,Lovell C.,Myers J.,Lipps Hogan J.,McGill J.B.,Salam M.,Schweiger T.,Kissel S.,Recklein C.,Clifton M.J.,Tamborlane W.,Camp A.,Gulanski B.,Pham K.,Alguard M.,Gatcomb P.,Lessard K.,Perez M.,Iannone L.,Magenheimer E.,Montosa A.,Cefalu W.T.,Fradkin J.,Burch H.B.,Bremer A.A.,Nathan D.M.,Lachin J.M.,Buse J.B.,Kahn S.E.,Larkin M.E.,Tiktin M.,Wexler D.,Burch H.B.,Bremer A.A.,Lachin J.M.,Bebu I.,Butera N.,Buys C.J.,Fagan A.,Gao Y.,Gramzinski M.R.,Hall S.D.,Kazemi E.,Legowski E.,Liu H.,Suratt C.,Tripputi M.,Arey A.,Backman M.,Bethepu J.,Lund C.,Mangat Dhaliwal P.,McGee P.,Mesimer E.,Ngo L.,Steffes M.,Seegmiller J.,Saenger A.,Arends V.,Gabrielson D.,Conner T.,Warren S.,Day J.,Huminik J.,Soliman E.Z.,Zhang Z.M.,Campbell C.,Hu J.,Keasler L.,Hensley S.,Li Y.,Herman W.H.,Kuo S.,Martin C.,Waltje A.,Mihalcea R.,Min D.J.,Perez-Rosas V.,Prosser L.,Resnicow K.,Ye W.,Shao H.,Zhang P.,Luchsinger J.,Sanchez D.,Assuras S.,Groessl E.,Sakha F.,Chong H.,Hillery N.,Abdouch I.,Bahtiyar G.,Brantley P.,Broyles F.E.,Canaris G.,Copeland P.,Craine J.J.,Fein W.L.,Gliwa A.,Hope L.,Lee M.S.,Meiners R.,Meiners V.,O’Neal H.,Park J.E.,Sacerdote A.,Sledge Jr E.,Soni L.,Steppel-Reznik J.,Turchin A.

Affiliation:

1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (J.B.G.).

2. Divisions of Cardiovascular and Preventive Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (B.M.E.).

3. The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville, MD (A.G., N.Y., H.K.-S.).

4. Division of Endocrinology, Kaiser Permanente of Georgia, Atlanta (J.B.).

5. Department of Endocrinology, Emory University School of Medicine, Atlanta, GA (J.B.).

6. Division of Diabetes, Endocrinology & Metabolism, University of Nebraska Medical Center, Omaha VA Medical Center (C.D.).

7. Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).

8. Division of Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC (Y.P.).

9. Division of Endocrinology, University of New Mexico School of Medicine, Albuquerque (D.S.).

10. VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM (A.S.).

11. Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor (M.H.T.).

12. Department of Medicine, VA Puget Sound and University of Washington, Seattle (K.M.U.).

13. VA San Diego Healthcare System and University of California, San Diego (S.M.).

Abstract

BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). METHODS: A total of 5047 participants with a mean±SD age of 57.2±10.0 years, type 2 diabetes duration of 4.0±2.7 years, and low baseline prevalence of cardiovascular disease (myocardial infarction, 5.1%; cerebrovascular accident, 2.0%) were followed for a median of 5 years. Prespecified outcomes included between-group time-to-first event analyses of MACE-3 (composite of major adverse cardiovascular events: cardiovascular death, myocardial infarction, and stroke), MACE-4 (MACE-3+unstable angina requiring hospitalization or revascularization), MACE-5 (MACE-4+coronary revascularization), MACE-6 (MACE-5+hospitalization for heart failure), and the individual components. MACE outcomes and hospitalization for heart failure in the liraglutide-treated group were compared with the other groups combined using Cox proportional hazards models. MACE-6 was also analyzed as recurrent events using a proportional rate model to compare all treatment groups. RESULTS: We observed no statistically significant differences in the cumulative incidence of first MACE-3, MACE-4, MACE-5, or MACE-6, or their individual components, by randomized treatment group. However, when compared with the other treatment groups combined, the liraglutide-treated group had a significantly lower risk of MACE-5 (adjusted hazard ratio, 0.70 [95% CI, 0.54–0.91]; P =0.021), MACE-6 (adjusted hazard ratio, 0.70 [95% CI, 0.55–0.90]; P =0.021), and hospitalization for heart failure (adjusted hazard ratio, 0.49 [95% CI, 0.28–0.86]; P =0.022). Compared with the liraglutide group, significantly higher rates of recurrent MACE-6 events occurred in the groups treated with glimepiride (rate ratio, 1.61 [95% CI, 1.13–2.29]) or sitagliptin (rate ratio 1.75; [95% CI, 1.24–2.48]). CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01794143.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference36 articles.

1. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes

2. Changes in Diabetes-Related Complications in the United States, 1990–2010

3. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

4. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

5. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Management of Obesity: A Comparison of Bariatric Metabolic Surgery and Novel Incretin Mimetic Drugs;Diabetes Technology & Therapeutics;2024-09-01

2. Finding Truth in Observational and Interventional Studies in Diabetes and Cardiovascular Disease;Journal of the American College of Cardiology;2024-09

3. Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis;Frontiers in Endocrinology;2024-05-31